# Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

> **NCT04692688** · PHASE2 · COMPLETED · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 103 (actual)

## Conditions studied

- Diabetic Retinopathy
- Diabetic Macular Edema
- NPDR - Non Proliferative Diabetic Retinopathy
- PDR - Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** APX3330
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04692688
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-08
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-01-25
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692688, "Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04692688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*